Drp1-Associated Mitochondrial Dysfunction Is Involved in PNA-TPP-Mediated Reduction of Cisplatin Tolerance in A549 Lung Adenocarcinoma Stem-like Spheres

Technical Summary: Drp1-Associated Mitochondrial Dysfunction in PNA-TPP-Mediated Reduction of Cisplatin Tolerance

Problem Statement
Cisplatin (CDDP) resistance remains a critical barrier to effective treatment in non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma. This resistance is closely linked to the presence of cancer stem-like cells (CSCs), which exhibit enhanced drug tolerance, self-renewal capabilities, and metabolic adaptations. Previous research suggests that mitochondrial status, including mass and function, plays a pivotal role in the formation of drug-resistant phenotypes. Specifically, the balance of mitochondrial dynamics (fission and fusion) and the function of Dynamin-related protein 1 (Drp1) are implicated in cell survival and chemotherapy response. However, the specific mechanisms by which mitochondrial dysfunction can be targeted to reverse cisplatin tolerance in lung adenocarcinoma stem-like spheres remain underexplored.

Methodology
The study utilized A549 lung adenocarcinoma cells to establish a stem-like sphere model via single-cell cloning and serum-free suspension culture. The primary intervention involved PNA-TPP, a peptide nucleic acid conjugated with triphenylphosphonium, designed to target the mitochondrial DNA D-loop regulatory region.

Key experimental approaches included:

• Intervention: Treatment with 10 nmol/mL PNA-TPP for 24 hours, alone or in combination with 80 µM cisplatin.
• Genetic Manipulation: Lentiviral-mediated overexpression (OE-Drp1) and shRNA-mediated knockdown (sh-Drp1) of Drp1 to validate its specific role.
• Functional Assays:
  • Viability and Clonogenicity: CCK-8 assays and colony formation assays.
  • Stemness Evaluation: Sphere formation assays and Western blotting for stemness markers (OCT4, SOX2, NANOG).
  • Mitochondrial Function: Assessment of mitochondrial membrane potential (JC-1 staining), reactive oxygen species (ROS) levels (DCFH-DA flow cytometry and DHE staining), and ATP levels (ELISA).
  • Apoptosis and Metastasis: Flow cytometry (Annexin V-FITC/PI), wound healing, and Transwell invasion assays.
  • Molecular Analysis: qRT-PCR and Western blotting to quantify Drp1 expression in total and mitochondrial protein fractions, as well as apoptosis-related proteins (Bcl-2, Bax).

Key Results

1. Characterization of Stem-like Spheres: A549-derived spheres exhibited lower mitochondrial Drp1 expression and an anti-apoptotic profile (high Bcl-2, low Bax) compared to parental A549 cells, confirming their stem-like and drug-tolerant nature.
2. PNA-TPP Induces Drp1 Upregulation and Mitochondrial Dysfunction: Treatment with PNA-TPP significantly increased Drp1 mRNA and mitochondrial protein levels. This was accompanied by a loss of mitochondrial membrane potential, a reduction in ATP levels, and a marked increase in intracellular ROS.
3. Suppression of Stemness and Cisplatin Tolerance: PNA-TPP treatment reduced sphere-forming ability and downregulated OCT4, SOX2, and NANOG expression. When combined with cisplatin, PNA-TPP pretreatment further enhanced the inhibition of cell viability, colony formation, migration, and invasion, while significantly increasing apoptosis rates compared to cisplatin alone.
4. Role of Drp1:
   • Overexpression: Drp1 overexpression mimicked the effects of PNA-TPP, inducing mitochondrial dysfunction (low potential, high ROS, low ATP) and reducing stemness markers. In the presence of cisplatin, Drp1 overexpression further suppressed colony formation and invasion while promoting apoptosis.
   • Knockdown: Silencing Drp1 partially reversed the mitochondrial membrane potential loss and restored sphere-forming ability and stemness marker expression in PNA-TPP-treated cells. This confirmed that Drp1 is a critical mediator of the observed effects, though not the sole factor.

Key Contributions

• Mechanistic Insight: The study identifies Drp1-associated mitochondrial dysfunction as a central mechanism through which PNA-TPP reduces cisplatin tolerance in lung adenocarcinoma stem-like cells.
• Therapeutic Strategy: It demonstrates that targeting mitochondrial DNA transcription via PNA-TPP can disrupt mitochondrial homeostasis, thereby weakening the stemness phenotype and sensitizing resistant cells to cisplatin.
• Validation of Drp1: The research establishes a causal link between Drp1 upregulation and the reversal of drug resistance, showing that Drp1 overexpression is sufficient to mimic the therapeutic benefits of PNA-TPP, while its knockdown attenuates them.

Significance and Claims
The authors claim that PNA-TPP may serve as a potential strategy to overcome cisplatin resistance in lung adenocarcinoma by inducing Drp1-associated mitochondrial dysfunction. The study posits that this dysfunction shifts the cellular state from a tolerant, stem-like phenotype to a stress-injury state, making the cells more susceptible to chemotherapy.

However, the paper maintains a modest tone regarding its conclusions. The authors explicitly acknowledge several limitations:

• The findings are primarily based on A549-derived spheres and have not yet been validated in other cell lines, primary tumor spheres, or in vivo models.
• The study did not systematically distinguish between the effects of PNA-TPP alone versus the combined treatment in all contexts, leaving the possibility of additive cytotoxicity.
• While Drp1 is shown to be a key component, the partial reversal observed upon knockdown suggests that PNA-TPP likely affects other mitochondrial processes (e.g., transcription, oxidative phosphorylation, fusion proteins) beyond just Drp1-mediated fission.
• The specific causal mechanism regarding Drp1 translocation, phosphorylation, and direct mitochondrial fission requires further verification through morphological imaging and additional molecular profiling.

In summary, the paper concludes that Drp1-related mitochondrial functional changes are an important component of the PNA-TPP response network that reduces cisplatin tolerance, but the specific causal pathways require further elucidation.